Kymab Wins UK Supreme Court Antibody Battle Against Regeneron
The UK Supreme Court has supported an appeal by British biotech Kymab to revoke antibody…
30/06/2020 - 4 minutes
Regeneron
Update: Fifth US Antibody Patent Owned by UK Biotech Upheld in Regeneron Battle
Update (04/06/2020): After upholding four of Kymab's patents addressing the production of antibody drugs earlier…
04/06/2020 - 4 minutes
Finnish Genetics Study Provides Clues for Treating Type 2 Diabetes
A genetic mutation common to Finnish populations has been found to protect against type 2…
04/11/2019 - 2 minutes
Dutch and US Biotechs Team Up Against HPV-related Cancer
ISA Pharmaceuticals will work together with Regeneron to combine its immunotherapy against cancer induced by…
18/12/2017 - 2 minutes
Biotech and Pharma Giants Make a Good Start to Phase II Trial for Skin Cancer
Regeneron and Sanofi have announced positive early results from a Phase II study investigating their…
13/12/2017 - 3 minutes
Update: The EU Approval of Dupixent Might Bring its Pricing Polemic to Europe
Update (01/10/2017): The European Commission has tighter control over pricing that governments have over here…
02/10/2017 - 1 minute
Wind Blown into the Sails of New Asthma Drug With Positive Phase III Results
A new asthma drug developed by Sanofi and Regeneron, dupilumab, has met its primary objectives…
11/09/2017 - 2 minutes
Checkpoint Inhibitor from Regeneron and Sanofi gets Priority After Breakup
The FDA has granted breakthrough therapy designation to Regeneron and Sanofi for cemiplimab, just a…
08/09/2017 - 1 minute
Regeneron Cuts Sanofi Loose as Antibody Development Partner
After a run of successful therapeutic antibodies, including a potential blockbuster, Regeneron says it will…
04/08/2017 - 2 minutes
UPDATE: EMA joins FDA in Approving Rheumatoid Arthritis Drug from Sanofi and Regeneron
UPDATE (27/06/2017): The EMA has followed suit by approving Kevzara for moderate to severe rheumatoid arthritis. UPDATE (23/05/2017): More…
27/06/2017 - 3 minutes
Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials
Bayer's and Regeneron's blockbuster Eylea could be facing serious competition, as Novartis boasts with positive…
20/06/2017 - 2 minutes
Get Ready for One of the Biggest New Drug Approvals of the Year
After Praluent, Sanofi and Regeneron have now scored their next drug approval with dupilumab, an antibody for the…
29/03/2017 - 3 minutes
